Y-320
Appearance
![]() | |
Names | |
---|---|
Preferred IUPAC name
1-(4-Chlorophenyl)-N-{3-cyano-4-[4-(morpholin-4-yl)piperidin-1-yl]phenyl}-5-methyl-1H-pyrazole-4-carboxamide | |
Other names
AGN-PC-03MFTL; SureCN6052244; Y-320-5mg; Y-320-10mg; Y-320-25mg; Y-320-50mg; s7516; IL-17 Inhibitor
| |
Identifiers | |
3D model (JSmol)
|
|
ChemSpider | |
PubChem CID
|
|
CompTox Dashboard (EPA)
|
|
| |
| |
Properties | |
C27H29ClN6O2 | |
Molar mass | 505.01116 g/mol |
Density | 1.347 g/cm3 |
Boiling point | 631.225 °C (1,168.205 °F; 904.375 K) at 760 mmHg |
Hazards | |
Flash point | 335.553 °C (635.995 °F; 608.703 K) |
Except where otherwise noted, data are given for materials in their standard state (at 25 °C [77 °F], 100 kPa).
|
Y-320 is an orally active immunomodulator, and inhibits IL-17 production by CD4 T cells stimulated with IL-15 with IC50 of 20 to 60 nM.[1]
Biological activity
[edit]In vitro
[edit]Y-320 also inhibits the production of IFN-γ and TNF-α by mouse CD4 T cells stimulated with IL-15, CXCL12, and anti-CD3 mAb.
In vivo
[edit]Y-320 (0.3-3 mg/kg p.o.) ameliorates collagen-induced arthritis (CIA) in mice with a reduction of IL-17 mRNA in arthritic joints, and also shows therapeutic effects on CIA in cynomolgus monkeys. Moreover, Y-320 shows a synergistic effect in combination with anti-TNF-α mAb on chronic-progressing CIA in mice.[2]
References
[edit]- ^ "Selleck Chemicals Y-320, IL-17 Inhibitor". 26 Sep 2014.
- ^ Ushio H, et al. (2013). "A new phenylpyrazoleanilide, y-320, inhibits interleukin 17 production and ameliorates collagen-induced arthritis in mice and cynomolgus monkeys". Pharmaceuticals. 7 (1): 1–17. doi:10.3390/ph7010001. PMC 3915191. PMID 24366113.